{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032175","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.866376+00:00","generated_at":"2026-06-10T21:51:02.770628+00:00","sec_items":["1.01","2.03","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cingulate reports Phase 3 CTx-1301 trend toward significance; insider debt conversion at premium","bullets":["Werth Family converted $5.8M debt/interest into 6.8M pre-funded warrants at $0.85/share (market $0.058).","Phase 3 adult trial did not meet primary endpoint (PERMP over 16h, p=0.089) but showed trend and effect sizes 1.41 at 30min, 0.98 at 16h.","CGI-S scores significantly improved (-1.2 vs 0.0, p<0.001); AISRS scores reduced by -16.3.","Safety favorable: only one mild AE in CTx-1301 group vs three in placebo; no insomnia reported.","NDA filing expected H2 2024; Phase 3 pediatric dose-optimization and fixed-dose trials ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032175","json":"https://secwatch.observer/filing/0001493152-23-032175.json","markdown":"https://secwatch.observer/filing/0001493152-23-032175.md","text":"https://secwatch.observer/filing/0001493152-23-032175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223032175/0001493152-23-032175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223032175/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:51:02.770628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a49465fa6b640677acb2de0f5e3d8f52d52b27e","claim":"Cingulate Inc. entered into Note Conversion Agreement with Werth Family Investment Associates LLC (effective 2023-09-08).","evidence_excerpt":"On September 8, 2023, the Company and CTx entered into a Note Conversion Agreement (the “Note Conversion Agreement”) with WFIA, pursuant to which WFIA agreed to convert the Original Principal Amount under the A&R Note plus all accrued interest thereon, or $5,812,500, into pre-funded warrants (“Pre-Funded Warrants”) to purchase 6,838,235 shares (“Pre-Funded Warrant Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223032175/0001493152-23-032175-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Werth Family Investment Associates LLC"},{"label":"Effective","value":"2023-09-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}